Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III

D. Hasdai, David Holmes, E. J. Topol, P. B. Berger, D. A. Criger, J. S. Hochman, E. R. Bates, A. Vahanian, P. W. Armstrong, R. Wilcox, E. M. Ohman, R. M. Califf

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Aims. Reteplase has been reported to achieve better patency of the infarct artery than alteplase. As infarct artery patency is strongly associated with survival among patients with cardiogenic shock, we postulated that treatment with reteplase would improve outcomes among shock patients. Methods. We compared 30-day mortality rates among patients in GUSTO-III who either presented with shock or developed shock after enrolment: all patients received either front-loaded alteplase or reteplase (two bolus doses of 10 MU, 30 min apart). Results. Shock occurred in 260 (5.3%) of 4921 patients randomized to alteplase and 560 (5.5%) of 10,138 patients randomized to reteplase. Of these patients, 28 (10.8%) and 55 (9.8%) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35%, and 37% of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (~11-13%) or surgical (~2-3%) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65%) and 353 (63%) shock patients randomized to alteplase and reteplase, respectively (P = 0.59). Of patients presenting with shock, 64% and 58% of patients randomized to alteplase or reteplase died within 30 days (P = 0.59). Conclusion. Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock.

Original languageEnglish (US)
Pages (from-to)128-135
Number of pages8
JournalEuropean heart journal
Volume20
Issue number2
DOIs
StatePublished - Jan 1 1999

Fingerprint

Cardiogenic Shock
Tissue Plasminogen Activator
Shock
Myocardial Infarction
reteplase
Arteries
Fibrinolytic Agents
Coronary Angiography

Keywords

  • Alteplase
  • Cardiogenic shock
  • Randomized clinical trial
  • Reteplase
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. / Hasdai, D.; Holmes, David; Topol, E. J.; Berger, P. B.; Criger, D. A.; Hochman, J. S.; Bates, E. R.; Vahanian, A.; Armstrong, P. W.; Wilcox, R.; Ohman, E. M.; Califf, R. M.

In: European heart journal, Vol. 20, No. 2, 01.01.1999, p. 128-135.

Research output: Contribution to journalArticle

Hasdai, D, Holmes, D, Topol, EJ, Berger, PB, Criger, DA, Hochman, JS, Bates, ER, Vahanian, A, Armstrong, PW, Wilcox, R, Ohman, EM & Califf, RM 1999, 'Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III', European heart journal, vol. 20, no. 2, pp. 128-135. https://doi.org/10.1053/euhj.1999.1282
Hasdai, D. ; Holmes, David ; Topol, E. J. ; Berger, P. B. ; Criger, D. A. ; Hochman, J. S. ; Bates, E. R. ; Vahanian, A. ; Armstrong, P. W. ; Wilcox, R. ; Ohman, E. M. ; Califf, R. M. / Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. In: European heart journal. 1999 ; Vol. 20, No. 2. pp. 128-135.
@article{347370e33c8743c1abab21172edfec31,
title = "Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III",
abstract = "Aims. Reteplase has been reported to achieve better patency of the infarct artery than alteplase. As infarct artery patency is strongly associated with survival among patients with cardiogenic shock, we postulated that treatment with reteplase would improve outcomes among shock patients. Methods. We compared 30-day mortality rates among patients in GUSTO-III who either presented with shock or developed shock after enrolment: all patients received either front-loaded alteplase or reteplase (two bolus doses of 10 MU, 30 min apart). Results. Shock occurred in 260 (5.3{\%}) of 4921 patients randomized to alteplase and 560 (5.5{\%}) of 10,138 patients randomized to reteplase. Of these patients, 28 (10.8{\%}) and 55 (9.8{\%}) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35{\%}, and 37{\%} of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (~11-13{\%}) or surgical (~2-3{\%}) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65{\%}) and 353 (63{\%}) shock patients randomized to alteplase and reteplase, respectively (P = 0.59). Of patients presenting with shock, 64{\%} and 58{\%} of patients randomized to alteplase or reteplase died within 30 days (P = 0.59). Conclusion. Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock.",
keywords = "Alteplase, Cardiogenic shock, Randomized clinical trial, Reteplase, Thrombolysis",
author = "D. Hasdai and David Holmes and Topol, {E. J.} and Berger, {P. B.} and Criger, {D. A.} and Hochman, {J. S.} and Bates, {E. R.} and A. Vahanian and Armstrong, {P. W.} and R. Wilcox and Ohman, {E. M.} and Califf, {R. M.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1053/euhj.1999.1282",
language = "English (US)",
volume = "20",
pages = "128--135",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III

AU - Hasdai, D.

AU - Holmes, David

AU - Topol, E. J.

AU - Berger, P. B.

AU - Criger, D. A.

AU - Hochman, J. S.

AU - Bates, E. R.

AU - Vahanian, A.

AU - Armstrong, P. W.

AU - Wilcox, R.

AU - Ohman, E. M.

AU - Califf, R. M.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Aims. Reteplase has been reported to achieve better patency of the infarct artery than alteplase. As infarct artery patency is strongly associated with survival among patients with cardiogenic shock, we postulated that treatment with reteplase would improve outcomes among shock patients. Methods. We compared 30-day mortality rates among patients in GUSTO-III who either presented with shock or developed shock after enrolment: all patients received either front-loaded alteplase or reteplase (two bolus doses of 10 MU, 30 min apart). Results. Shock occurred in 260 (5.3%) of 4921 patients randomized to alteplase and 560 (5.5%) of 10,138 patients randomized to reteplase. Of these patients, 28 (10.8%) and 55 (9.8%) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35%, and 37% of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (~11-13%) or surgical (~2-3%) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65%) and 353 (63%) shock patients randomized to alteplase and reteplase, respectively (P = 0.59). Of patients presenting with shock, 64% and 58% of patients randomized to alteplase or reteplase died within 30 days (P = 0.59). Conclusion. Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock.

AB - Aims. Reteplase has been reported to achieve better patency of the infarct artery than alteplase. As infarct artery patency is strongly associated with survival among patients with cardiogenic shock, we postulated that treatment with reteplase would improve outcomes among shock patients. Methods. We compared 30-day mortality rates among patients in GUSTO-III who either presented with shock or developed shock after enrolment: all patients received either front-loaded alteplase or reteplase (two bolus doses of 10 MU, 30 min apart). Results. Shock occurred in 260 (5.3%) of 4921 patients randomized to alteplase and 560 (5.5%) of 10,138 patients randomized to reteplase. Of these patients, 28 (10.8%) and 55 (9.8%) randomized to alteplase and reteplase, respectively, presented with shock. In-hospital, 35%, and 37% of shock patients assigned to alteplase or reteplase, respectively, underwent coronary angiography, with similar rates of percutaneous (~11-13%) or surgical (~2-3%) revascularization procedures subsequently performed. Death within 30 days occurred in 169 (65%) and 353 (63%) shock patients randomized to alteplase and reteplase, respectively (P = 0.59). Of patients presenting with shock, 64% and 58% of patients randomized to alteplase or reteplase died within 30 days (P = 0.59). Conclusion. Compared with alteplase, reteplase did not improve outcome among patients who presented with shock or developed shock after receiving thrombolytics. The newer-generation thrombolytic agents remain of limited efficacy in the treatment and prevention of shock.

KW - Alteplase

KW - Cardiogenic shock

KW - Randomized clinical trial

KW - Reteplase

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=0032911136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032911136&partnerID=8YFLogxK

U2 - 10.1053/euhj.1999.1282

DO - 10.1053/euhj.1999.1282

M3 - Article

C2 - 10099909

AN - SCOPUS:0032911136

VL - 20

SP - 128

EP - 135

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -